Abstract：
UNASSIGNED: Central nervous system infections (CNSI) disproportionately affect individuals in low-resource settings where diagnosis is challenging; large proportions of patients never receive a confirmed microbiological diagnosis resulting in inadequate management and high mortality. The epidemiology of CNSI varies globally and conventional diagnostics deployed in resource-limited settings have significant limitations, with an urgent need for improved diagnostic strategies.
UNASSIGNED: This review describes molecular platforms and other novel diagnostics used in the diagnosis of CNSI that are applicable to resource-limited settings. An extensive literature search of Medline and PubMed was performed. The emphasis is on investigations targeting infections of relevance to resource-limited settings either due to variation in regional CNSI epidemiology or due to increased prevalence in patients with immunosuppression. This includes commercially available multiplex PCR platforms, mycobacterial PCR platforms, and rapid diagnostics tests. To offer a framework for the optimal implementation in clinical settings, existing evidence highlighting the advantages and limitations of available platforms is reviewed.
UNASSIGNED: The implementation of molecular platforms and other novel diagnostics has the potential to transform CNSI diagnosis in resource-limited settings, with several examples of successful rollout of novel diagnostics such as Xpert MTB/RIF Ultra and cryptococcal antigen testing.
UNASSIGNED: This review describes molecular platforms and other novel diagnostics used in the diagnosis of CNSI that are applicable to resource-limited settings. An extensive literature search of Medline and PubMed was performed. The emphasis is on investigations targeting infections of relevance to resource-limited settings either due to variation in regional CNSI epidemiology or due to increased prevalence in patients with immunosuppression. This includes commercially available multiplex PCR platforms, mycobacterial PCR platforms, and rapid diagnostics tests. To offer a framework for the optimal implementation in clinical settings, existing evidence highlighting the advantages and limitations of available platforms is reviewed.
UNASSIGNED: The implementation of molecular platforms and other novel diagnostics has the potential to transform CNSI diagnosis in resource-limited settings, with several examples of successful rollout of novel diagnostics such as Xpert MTB/RIF Ultra and cryptococcal antigen testing.
摘要：
■中枢神经系统感染（CNSI）不成比例地影响低资源环境中的个体，在这些环境中，诊断具有挑战性；大部分患者从未接受过确认的微生物学诊断，导致管理不足和高死亡率。CNSI的流行病学在全球范围内各不相同，在资源有限的环境中部署的常规诊断方法具有很大的局限性，迫切需要改进的诊断策略。
■这篇综述描述了分子平台和其他用于CNSI诊断的新颖诊断方法，这些方法适用于资源有限的环境。对Medline和PubMed进行了广泛的文献检索。重点是针对与资源有限的环境相关的感染的调查，这是由于区域CNSI流行病学的变化或由于免疫抑制患者的患病率增加。这包括市售的多重PCR平台，分枝杆菌PCR平台，和快速诊断测试。为临床环境中的最佳实施提供框架，审查了强调可用平台优点和局限性的现有证据。
■分子平台和其他新型诊断的实施有可能在资源有限的环境中改变CNSI诊断，有几个成功推出新型诊断的例子，如XpertMTB/RIFUltra和隐球菌抗原测试。
■这篇综述描述了分子平台和其他用于CNSI诊断的新颖诊断方法，这些方法适用于资源有限的环境。对Medline和PubMed进行了广泛的文献检索。重点是针对与资源有限的环境相关的感染的调查，这是由于区域CNSI流行病学的变化或由于免疫抑制患者的患病率增加。这包括市售的多重PCR平台，分枝杆菌PCR平台，和快速诊断测试。为临床环境中的最佳实施提供框架，审查了强调可用平台优点和局限性的现有证据。
■分子平台和其他新型诊断的实施有可能在资源有限的环境中改变CNSI诊断，有几个成功推出新型诊断的例子，如XpertMTB/RIFUltra和隐球菌抗原测试。
